CPC Biotech and Multiply Labs Advance Cell Therapy Automation

New Robot-Compatible Sterile Connectors Enhance Cell Therapy Manufacturing

Roseville, Minn. – May 5, 2026 – CPC Biotech, part of PSG and Dover and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceutical processing, has collaborated with Multiply Labs to rapidly advance the use of robotic systems in cell therapy manufacturing.

“Automation and the use of robotics are key in getting advanced therapies to patients more quickly,” said Troy Ostreng, senior product manager for CPC Biotech’s biopharmaceutical and cell and gene therapy (CGT) businesses. “To meet the growing needs for faster, more efficient, high-quality cell therapy manufacturing, we’re developing a first-ever aseptic connector designed for robotic operation,” he added.

San Francisco-based Multiply Labs is a pioneer in applying robotics in the production of cell and gene therapy products. Their unique modular approach is designed to reduce manufacturing bottlenecks, minimize the risks of human contamination, and broaden access to therapies.

“Today, cell therapy is done completely manually,” said Fred Parietti, Multiply Lab’s co-founder and CEO. “With robotic processes, we can unlock a level of scale and affordability that has not been possible before with manual approaches.” A study comparing traditional manual cell therapy to a robotic process found a cost reduction of more than 70%.¹

Human operators—a frequent source of contaminants in processing—do not enter Multiply Lab’s self-contained sterile processing robotic system, so the components within must be effectively managed by robots. CPC Biotech’s new robot-optimized solution combines the company’s groundbreaking MicroCNX® Nano Series aseptic connectors with a proprietary interface for handling by the robotic grippers.

“Robots still have difficulty handling soft material like bags or tubing,” said Ostreng. “A rigid connector at the end of tubing is something robotic grippers can operate in a stable, repeatable way. This new connector will help make robotics-based cell therapy automation possible.”

Both CPC Biotech and Multiply Labs share interests and capabilities in maximizing production capacity in a compact footprint. “It’s important for us to fit easily on the production floor,” said Parietti. The companies also focus on ease of use, reliability, modularity and scalability.

“Reliability, repeatability, and simplification are among the factors that will help cell therapy manufacturers adopt an automated approach with confidence,” said Ostreng. “In the end, we’re all working to get therapies to the people who need them more quickly, affordably and efficiently.”

To learn more about CPC Biotech connectors in automated cell therapy applications, stop by Booth 1555 at the American Society of Gene & Cell Therapy meeting in Boston, May 11-15.

For more information about the performance and versatility of MicroCNX connectors, visit cpc-bio.com.To learn more about Multiply Labs, visit multiplylabs.com.

About CPC Biotech

CPC Biotech is at the forefront of bioprocessing fluid management and flow control, offering a comprehensive portfolio of critical components: connectors, pumps, flow meters and sensors. Our industry-leading products permit biopharma innovators to produce next-generation biologics and therapeutics with optimal integrity, yield, efficiency and scalability. From lab to commercial launch, we enable those who drive breakthroughs in medicines and biologics that transform lives and advance humanity. CPC Biotech is part of Pump Solutions Group (PSG), an operating company within Dover Corporation. To learn more about CPC Biotech, please visit cpc-bio.com.

About Multiply Labs

Multiply Labs is a robotics company pioneering Physical AI for Life Sciences. The company develops the full stack for advanced biological manufacturing, including proprietary software, robotic systems, and consumables. Multiply Labs enables the scalable production of advanced biological therapies, starting with cell and gene therapies, the most complex manufacturing challenge in medicine. With a multidisciplinary team of engineers, computer scientists, and biologists, Multiply Labs is bridging the gap between advanced robotics and biomanufacturing. Based in San Francisco, Multiply Labs works with global leaders in biopharma to automate the production of tomorrow’s medicines. For more information, visit multiplylabs.com.

###

¹ See supplementary material in Melocchi, Alice, et al. Development of a robotic cluster for automated and scalable cell therapy manufacturing. Cytotherapy, 26 (9) (2024), pp.1095-1104.

Editorial Contact:
Jana Stender | CPC Biotech

• Tel: +1 (612) 564-2053
• Email: jana.stender@cpc-bio.com